Palbociclib Improved Survival in Metastatic Breast Cancer Trial
The PATINA trial found that adding the therapy extended progression-free survival for specific breast cancer patients.
Updated on Sept. 22, 2026 in Cancer
Live Poll
Is it acceptable to accept higher side effect risks for potentially longer progression-free cancer survival?
The phase 3 PATINA trial demonstrated that adding palbociclib to maintenance therapy significantly extended progression-free survival in patients with hormone receptor-positive, HER2-positive metastatic breast cancer. Patients treated with the combination achieved a median progression-free survival of 44.3 months, compared to 29.1 months for those receiving standard maintenance care.
Why it matters
Targeting both hormone receptor and HER2 pathways simultaneously addresses the dual signaling dependencies often seen in this specific type of metastatic breast cancer. This combined approach aims to delay disease progression by hitting multiple biological vulnerabilities at once.
The study involved 261 patients in the treatment arm and 257 in the control arm, showing a hazard ratio for progression-free survival of 0.75. However, neutropenia occurred in 77.8% of those receiving palbociclib compared to 7.7% of the control group.
The players
Cleveland Clinic
This academic medical center is the primary institution associated with the oncologists reporting on the clinical findings.
The details
The trial focused on patients who had not progressed after initial therapy, assigning them to receive either maintenance trastuzumab and endocrine therapy or the same regimen augmented with palbociclib. While the combination improved survival outcomes, it also led to higher rates of side effects including neutropenia and diarrhea.
Timeline
September 22, 2026: OncLive published the report detailing the PATINA trial data.
The Big Picture
The findings from the PATINA trial follow a pattern set by previous dual-pathway inhibition studies in oncology. The study results represent a specific data output from this ongoing research program.
Patients may experience a significant increase in progression-free time but should prepare for potential side effects such as neutropenia and diarrhea. Consulting with an oncologist regarding these clinical trial results is recommended to determine if this therapy fits an individual treatment plan.
The takeaway
This trial highlights the potential of combining targeted therapies to improve outcomes in complex breast cancer cases. Patients and providers should weigh the improved progression-free survival against the manageable but increased risk of treatment-related side effects.
Further reading
For more information on current treatment landscapes, visit the Cancer section.
More information
View the full ClinicalTrials.gov record for PATINA trial for study methodology.
Live Poll
Is it acceptable to accept higher side effect risks for potentially longer progression-free cancer survival?
